Back to discover
Drug

Isoflurane

In clinical development
ClassGABA-A receptor; anion channel positive allosteric modulatorEmerging researchLate-stage development
Also known as Fluriso, Forane, IsoSol, Isospire+4 more

Fluriso, Forane, IsoSol, Isospire, Terrell, Isoflurano, 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether, Isofluranum.

1
Research papers
6
Active clinical trials
23
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Inhaled Sedation in Critically Ill Patients: a Multicentre Randomized Clinical Trial

Clinical trial2026-06-29Results expected Q1 2027 · ClinicalTrials.gov

Sevoflurane/Dexmedetomidine vs. Isoflurane and Their Effects on Pediatric Emergence Delirium

Clinical trial2025-12-16Results expected Q4 2026 · ClinicalTrials.gov

Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits.

Research2003-02-01The Journal of neuroscience : the official journal of the Society for Neuroscience

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Isoflurane
Aliases & brands
FlurisoForaneIsoSolIsospireTerrellIsoflurano1-chloro-2,2,2-trifluoroethyl difluoromethyl etherIsofluranum
RxNorm CUI
6026
ChEMBL ID
CHEMBL1256
ATC codes
N01AB06
UNII
CYS9AKD70P
Primary mechanism
GABA-A receptor; anion channel positive allosteric modulator

Pharmacology & targets

23 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulator
POSITIVE MODULATORGlycine receptor (alpha-1/beta) positive modulator
POSITIVE MODULATORGlycine receptor (alpha-1/beta) positive modulator
OPENERPotassium channel subfamily K member 10 opener
OPENERPotassium channel subfamily K member 18 opener
OPENERPotassium channel subfamily K member 3 opener
OPENERPotassium channel subfamily K member 9 opener
OPENERPotassium channel subfamily K member 2 opener

Clinical trials

50 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
50
registered trials across all phases
LATEST COMPLETION 2024
6
Active studies
6
Recruiting
43
Late-stage (III+)
31
Completed
13
Discontinued
PHASE DISTRIBUTIONn = 50
Phase 15Phase 22Phase 2 / 31Phase 38Phase 410Phase N / A24

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2003 · 1,387 cites
Recent papers

Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2003 · 1,387 cites
Journals, researchers & institutions
Top journals
  • The Journal of neuroscience : the official journal of the Society for Neuroscience1
Leading researchers
  • Benshoff ND1
  • Dikranian K1
  • Hartman RE1
  • Izumi Y1
  • Jevtovic-Todorovic V1
  • Olney JW1
  • Wozniak DF1
  • Zorumski CF1
Leading institutions
free-text, unnormalised
  • University of Virginia Health System1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Acts on the same molecular target as Isoflurane, with 4 overlapping disease areas.

16 shared targets4 shared diseases1 shared paper

Studied across 4 of the same disease areas as Isoflurane in the shared literature.

4 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials